TODAY IN ONCOLOGY /news/june-2020/addition-of-rituximab-to-standard-chemotherapy-in-pediatric-patients-with-high-risk-mature-b-cell-non-hodgkin-lymphoma/ In a phase III trial reported in The New England Journal of Medicine, Minard‑Colin et al found that the addition of rituximab to standard Lymphomes Malin B chemotherapy significantly improved event-free and overall survival in children with high-risk, mature B-cell non-Hodgkin lymphoma.

]]>
Article /news/june-2020/long-term-survival-outcomes-with-3-years-vs-1-year-of-adjuvant-imatinib-for-high-risk-gist/ In a 10-year follow-up of the phase III SSGXVIII/AIO trial reported in JAMA Oncology, Heikki Joensuu, MD, and colleagues found that 3 years vs 1 year of adjuvant treatment with imatinib was associated with superior overall survival among patients with high-risk gastrointestinal stromal tumors.

]]>
Article /news/june-2020/effect-of-radiation-boost-to-residual-disease-in-high-risk-neuroblastoma/ In an analysis from the Children’s Oncology Group (COG) ANBL0532 study reported in the Journal of Clinical Oncology, Liu et al found that a radiotherapy boost to the gross residual tumor in patients with high-risk neuroblastoma did not appear to improve outcomes compared with patients in another COG cohort in which no boost to residual tumor was administered.  

]]>
Article TP53 R337H Mutations]]> /news/june-2020/variant-in-gene-may-increase-cancer-risk-in-those-with-common-tp53-r337h-mutations/ Scientists studying a common TP53 R337H variant found among people of Brazilian descent found that a variant in the tumor-suppressor gene XAF1 increases cancer risk when combined with the inherited TP53 R337H mutation. These findings were published by Pinto et al in Science Advances.

]]>
Article /news/june-2020/sedentary-behavior-and-risk-of-cancer-mortality/ In a study that investigated objective measures of sedentary behavior and cancer mortality, researchers found that greater inactivity was independently associated with a higher risk of dying from cancer. An accelerometer was used to measure physical activity, rather than relying on participants to self-report their activity levels. These findings were reported by Gilchrist et al in JAMA Oncology.

]]>
Article
THE ASCO POST PODCAST /podcasts/covid-19-research-from-the-asco20-virtual-scientific-program/ /media/14013310/ep54_graphic_covid19.jpg With this week bringing record highs of COVID-19 infection across the nation, on The ASCO Post Podcast, we're revisiting two presentations from the ASCO20 Virtual Scientific Program on the effect of the virus on patients with cancer.

]]>
Podcast
NEWSREELS FROM THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM /videos/asco20-virtual-scientific-program/scott-kopetz-on-encorafenib-plus-cetuximab-with-or-without-binimetinib-in-colorectal-cancer/ https://cf-images.us-east-1.prod.boltdns.net/v1/static/5813221795001/1f2a8ff3-ea18-494b-92d8-5b5c794d5d14/13142e7a-bf20-4dd1-90df-7008abb0ac6e/1280x720/match/image.jpg Scott Kopetz, MD, PhD, on encorafenib plus cetuximab with or without binimetinib for colorectal cancer

]]>
Video /videos/asco20-virtual-scientific-program/rana-mckay-on-intense-adt-before-radical-prostatectomy/ https://cf-images.us-east-1.prod.boltdns.net/v1/static/5813221795001/7bec16a8-bebe-4972-abfd-b6d350f92ffb/ae7ba243-5a18-40ec-81c6-ccd019884c61/1280x720/match/image.jpg Rana R. McKay, MD, on intense androgen-deprivation therapy before radical prostatectomy

]]>
Video
TRENDING IN COLORECTAL CANCER /issues/june-10-2020/pembrolizumab-doubles-progression-free-survival-in-msi-hdmmr-metastatic-colorectal-cancer/ Article /news/june-2020/cisplatinfluorouracil-vs-carboplatinpaclitaxel-in-chemotherapy-naive-patients-with-advanced-anal-cancer/ In an International Rare Cancers Initiative phase II trial (InterAAct) reported in the Journal of Clinical Oncology, Rao et al found that carboplatin/paclitaxel was associated with less serious toxicity and a trend toward improved overall survival vs cisplatin/fluorouracil in chemotherapy-naive patients with advanced anal cancer.

]]>
Article /issues/june-25-2020/trastuzumab-deruxtecan-shows-benefit-in-refractory-colorectal-cancer/ Having recently gained approval in metastatic breast cancer, fam-trastuzumab deruxtecan-nxki (T-DXd) is now proving its worth in metastatic colorectal cancer, according to results of the phase II DESTINY-CRC01 study in patients with HER2-positive disease.

]]>
Article /issues/june-25-2020/survey-shows-young-onset-colorectal-cancer-may-be-overlooked-in-exam-rooms/ Article
COVID-19 NEWS AND RESOURCES FROM THE ASCO POST /news/july-2020/continuous-coverage-of-covid-19/ Article